AP&T: 更年期激素疗法和结直肠癌的风险降低有关

2021-05-11 MedSci原创 MedSci原创

人体内激素水平与各种疾病的发生都有相关性,比如妇女在绝经后出现关节疼痛,骨质疏松,心血管疾病和肿瘤的出现。

      人体内激素水平与各种疾病的发生都有相关性,比如妇女在绝经后出现关节疼痛,骨质疏松血管疾病和肿瘤的出现。而有研究显示激素替代疗法有助于降低绝经女性患结肠癌的风险。本项研究旨在进一步探究更年期激素疗法(MHT)和结直肠癌的风险之间关系。

 

      研究人员搜集了2005年至2021年间瑞典所有接受过MHT的女性患者(n = 290 186),然后按1:3的比例将非使用者进行匹配。药物启动后的所有CRC病例均在瑞典癌症登记处进行记录。通过多变量和Cox回归模型评估该关联。

 

      研究结果显示与非MHT使用者相比,MHT使用者的结肠癌(OR = 0.67,95%CI 0.63-0.72)和直肠腺癌(OR = 0.66,95%CI 0.60-0.73)的总体风险降低,尤其是在40-60岁的女性中这样的现象更为明显。与非MHT使用者相比,仅使用雌激素制剂(E‐MHT)和雌三醇的患癌几率最低降低(OR = 0.73,95%CI 0.65-0.8)。过去使用过E-MHT也可以很大幅度的降低患癌风险(OR = 0.49,95%CI 0.43-0.56)。但是接受雌激素联合孕激素疗法(EP‐MHT)的降低患癌几率幅度不大(结肠腺癌OR 0.62,95%CI 0.54-0.72;直肠腺癌OR = 0.60,95%CI 0.49-0.74)。

 

      本项研究显示对于接受E‐MHT和EP‐MHT的患者来说,降低结肠癌的风险的效果并不明显,但是单独使用MHT可能会降低结直肠腺癌的风险。

 

 

原始出处:

Qing Liu. Et al. Menopausal hormone therapies and risk of colorectal cancer: a Swedish matched‐cohort study. Aliment Pharmacol Ther. 2021.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1820720, encodeId=5f961820e203b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Nov 17 01:56:55 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453507, encodeId=a27a145350ebf, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu May 13 12:56:55 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531173, encodeId=c30b15311e36f, content=<a href='/topic/show?id=ad8f668407d' target=_blank style='color:#2F92EE;'>#激素疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66840, encryptionId=ad8f668407d, topicName=激素疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=822512217606, createdName=lisa442, createdTime=Thu May 13 12:56:55 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964739, encodeId=ac20964e39a4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81ac5180803, createdName=146f77a4m34暂无昵称, createdTime=Tue May 11 22:02:00 CST 2021, time=2021-05-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1820720, encodeId=5f961820e203b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Nov 17 01:56:55 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453507, encodeId=a27a145350ebf, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu May 13 12:56:55 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531173, encodeId=c30b15311e36f, content=<a href='/topic/show?id=ad8f668407d' target=_blank style='color:#2F92EE;'>#激素疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66840, encryptionId=ad8f668407d, topicName=激素疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=822512217606, createdName=lisa442, createdTime=Thu May 13 12:56:55 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964739, encodeId=ac20964e39a4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81ac5180803, createdName=146f77a4m34暂无昵称, createdTime=Tue May 11 22:02:00 CST 2021, time=2021-05-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1820720, encodeId=5f961820e203b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Nov 17 01:56:55 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453507, encodeId=a27a145350ebf, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu May 13 12:56:55 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531173, encodeId=c30b15311e36f, content=<a href='/topic/show?id=ad8f668407d' target=_blank style='color:#2F92EE;'>#激素疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66840, encryptionId=ad8f668407d, topicName=激素疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=822512217606, createdName=lisa442, createdTime=Thu May 13 12:56:55 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964739, encodeId=ac20964e39a4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81ac5180803, createdName=146f77a4m34暂无昵称, createdTime=Tue May 11 22:02:00 CST 2021, time=2021-05-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1820720, encodeId=5f961820e203b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Nov 17 01:56:55 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453507, encodeId=a27a145350ebf, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu May 13 12:56:55 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531173, encodeId=c30b15311e36f, content=<a href='/topic/show?id=ad8f668407d' target=_blank style='color:#2F92EE;'>#激素疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66840, encryptionId=ad8f668407d, topicName=激素疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=822512217606, createdName=lisa442, createdTime=Thu May 13 12:56:55 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964739, encodeId=ac20964e39a4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81ac5180803, createdName=146f77a4m34暂无昵称, createdTime=Tue May 11 22:02:00 CST 2021, time=2021-05-11, status=1, ipAttribution=)]
    2021-05-11 146f77a4m34暂无昵称

    学习

    0

相关资讯

BMC Gastroenterology:与选择性结直肠癌手术患者生存结局相关的危险因素究竟有哪些?

结直肠癌(CRC)导致的癌症相关死亡约占全球每年诊断出的所有癌症和与癌症相关的死亡的10%,总体而言,CRC是发病率排名第三的癌症,是目前全球性的公共卫生问题。

JAMA:塞来昔布联合FOLFOX标准辅助化疗对结肠癌患者无病生存率的影响

对于III期结肠癌患者中,在FOLFOX标准辅助化疗方案中加入塞来昔布对患者3年无病生存率无提高作用

Gastroenterology:一种新型益生菌——嗜热链球菌可以抑制结直肠肿瘤发生

大肠癌(CRC)是全球第三大常见癌症,也是第四大癌症相关死亡的主要原因。

Gastroenterology :45岁后要定期做肠镜

45-49岁时接受结肠镜检查与随后的大肠癌发病率显著降低有很强的相关性。

Br J Cancer:结肠癌患者术前全身炎症反应(SIR)测定的预后价值

每年全球大约诊断出120万例新的结肠癌病例以及约有500,000例的死亡病例。

Clin Gastroenterology H: 结肠镜检查后腺瘤检出率和腺瘤特征与结直肠癌死亡率直接相关

结直肠癌(CRC)是美国癌症死亡的第三大主要原因,每年因CRC死亡的患者达50,000多名。